Compare SOLS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | CYTK |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | United States | United States |
| Employees | 4400 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 10.7B |
| IPO Year | N/A | 2004 |
| Metric | SOLS | CYTK |
|---|---|---|
| Price | $60.41 | $80.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $79.25 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 4.1M | 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $6.36 | $7.37 |
| Revenue Next Year | $5.64 | $310.19 |
| P/E Ratio | $54.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.43 | $32.89 |
| 52 Week High | $90.80 | $88.31 |
| Indicator | SOLS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 50.24 |
| Support Level | $56.20 | $59.07 |
| Resistance Level | $83.53 | $88.31 |
| Average True Range (ATR) | 3.10 | 2.99 |
| MACD | 0.02 | -0.66 |
| Stochastic Oscillator | 32.08 | 26.60 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.